Comparative studies of guanfacine and methyldopa.

Roeckel, A.; Heidland, A.

doi:10.1111/j.1365-2125.1980.tb04905.x

Cited by 5 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mean arterial pressure (calculated as, diastolic pressure + one third of pulse pressure) is reduced at 4 weeks by 17 per cent both with guanfacine and alpha‐methyldopa and at 8 weeks by 13 per cent and 16 per cent respectively. The reduction in mean arterial pressure with guanfacine is of the same order as found by Jerie 4 (1979) in a long term treatment with guanfacine but is much less than 24 per cent reported by Roeckel and Heidland 5 (1979) after 6 weeks of treatment.…”

Section: Discussionsupporting

confidence: 69%

A Comparative Study of A New Alpha‐Adrenoceptor Agonist, Guanfacine and Alpha‐Methyldopa in The Treatment of Hypertension

Joshi¹,

De²,

Cameron³

1984

Int J Clinical Practice

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 69%

A Comparative Study of A New Alpha‐Adrenoceptor Agonist, Guanfacine and Alpha‐Methyldopa in The Treatment of Hypertension

Joshi¹,

De²,

Cameron³

1984

Int J Clinical Practice

View full text Add to dashboard Cite

Antihypertensive Efficacy of Guanfacine and Methyldopa in Patients with Mild to Moderate Essential Hypertension

Wilson¹,

Blackshear

Parsons

et al. 1991

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Guanfacine, an alpha-2 adrenoceptor agonist, was compared with methyldopa as step-2 therapy for patients with mild-to-moderate essential hypertension in a 12-week, double-blind, randomized, parallel evaluation of efficacy and safety. The study consisted of a 2-week screening/weaning period (phase I), a 3-week treatment period with a diuretic (phase II), and a 12-week treatment period with a diuretic plus methyldopa or guanfacine (phase III). Patients were weaned from prior anti-hypertensive medication during the screening/weaning period and began receiving chlorthalidone 25 mg every morning. Patients received only 25 mg of chlorthalidone each morning during the phase II period. Those who had an average seated diastolic blood pressure (BP) of 95-114 mm Hg at the end of the phase II period were eligible to enter the phase III period and were randomly assigned to chlorthalidone plus guanfacine, 1 mg every night, or methyldopa, 250 mg tid. Seated and standing systolic and diastolic BP and pulses were measured biweekly for 12 weeks after randomization. Of the 112 patients who were randomly assigned to guanfacine or methyldopa, 87% completed the entire study. The mean seated systolic and diastolic BP were reduced 13/13 mm Hg by guanfacine administration and 15/13 mm Hg by methyldopa administration. No significant changes in seated pulse were seen in either group. Similar changes occurred in the standing position. Very few adverse effects were reported during the study, the most prevalent side effect was xerostomia (13% guanfacine, 9% methyldopa). No significant differences were observed between treatment groups for the incidence of cardiac arrhythmias after methyldopa or guanfacine administration was stopped.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Systemic and cardiac haemodynamic interactions between guanfacine and hydrallazine in hypertensive patients

Velasco

Urbina-Quintana

Morillo

et al. 1984

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The effect of guanfacine and hydrallazine on cardiovascular haemodynamics and on sympathetic nervous activity has been studied in 16 patients with essential hypertension. Two groups of patients were investigated: in Group A guanfacine brought the blood pressure back to normal (diastolic blood pressure less than or equal to 90 mmHg), and in Group B diastolic blood pressure was greater than 90 mmHg and required the addition of hydrallazine. Guanfacine significantly decreased heart rate, plasma renin activity and urinary excretion of noradrenaline, without altering cardiac contractility. In Group B, guanfacine 2 to 6 mg/day produced a significant decrease in blood pressure from 178.7/112.4 to 164.4/102.9 mmHg and in heart rate from 77.1 to 62.7 beats/min after 4 weeks of treatment. Guanfacine did not significantly alter preejection period, cardiac output or total peripheral resistance. Hydrallazine 50 to 300 mg/day caused a further reduction in blood pressure from 164.4/102.9 to 150.7/90.2 mmHg and an increase in heart rate from 62.7 to 72.1 beats/min. Limb blood flow was increased from 4.55 to 5.93 ml/100 g/min and limb vascular resistance was decreased from 39.55 to 23.6 mmHg 100 g X min/ml. Hydrallazine also caused a slight increase in plasma renin activity and urinary excretion of noradrenaline. It is concluded that guanfacine is a useful agent to block a hydrallazine-induced increase in sympathetic nervous activity.

show abstract

Comparative studies of guanfacine and methyldopa.

Cited by 5 publications

References 13 publications

A Comparative Study of A New Alpha‐Adrenoceptor Agonist, Guanfacine and Alpha‐Methyldopa in The Treatment of Hypertension

A Comparative Study of A New Alpha‐Adrenoceptor Agonist, Guanfacine and Alpha‐Methyldopa in The Treatment of Hypertension

Antihypertensive Efficacy of Guanfacine and Methyldopa in Patients with Mild to Moderate Essential Hypertension

Systemic and cardiac haemodynamic interactions between guanfacine and hydrallazine in hypertensive patients

Contact Info

Product

Resources

About